Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data.

Autor: van der Lee M; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands.; Leiden Network for Personalised Therapeutics, 2333 ZA Leiden, Netherlands., Allard WG; Department of Human Genetics, Leiden University Medical Center, 2333 ZA Leiden, Netherlands.; Leiden Genome Technology Center, Leiden University Medical Center, 2333 ZA Leiden, Netherlands., Vossen RHAM; Department of Human Genetics, Leiden University Medical Center, 2333 ZA Leiden, Netherlands.; Leiden Genome Technology Center, Leiden University Medical Center, 2333 ZA Leiden, Netherlands., Baak-Pablo RF; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands., Menafra R; Department of Human Genetics, Leiden University Medical Center, 2333 ZA Leiden, Netherlands.; Leiden Genome Technology Center, Leiden University Medical Center, 2333 ZA Leiden, Netherlands., Deiman BALM; Clinical Laboratory, Catharina Hospital Eindhoven, 5623 EJ Eindhoven, Netherlands., Deenen MJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands.; Department of Clinical Pharmacy, Catharina Hospital Eindhoven, 5623 EJ Eindhoven, Netherlands., Neven P; University Hospital Leuven, 3000 Leuven, Belgium., Johansson I; Department of Physiology and Pharmacology, Karolinska Institutet, Biomedicum 5B, 171 77 Solna, Sweden., Gastaldello S; Department of Physiology and Pharmacology, Karolinska Institutet, Biomedicum 5B, 171 77 Solna, Sweden., Ingelman-Sundberg M; Department of Physiology and Pharmacology, Karolinska Institutet, Biomedicum 5B, 171 77 Solna, Sweden., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands.; Leiden Network for Personalised Therapeutics, 2333 ZA Leiden, Netherlands., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands. j.j.swen@lumc.nl yahya.anvar@okra.ai.; Leiden Network for Personalised Therapeutics, 2333 ZA Leiden, Netherlands., Anvar SY; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands. j.j.swen@lumc.nl yahya.anvar@okra.ai.; Leiden Network for Personalised Therapeutics, 2333 ZA Leiden, Netherlands.; Department of Human Genetics, Leiden University Medical Center, 2333 ZA Leiden, Netherlands.; Leiden Genome Technology Center, Leiden University Medical Center, 2333 ZA Leiden, Netherlands.

Publikováno v: Science translational medicine [Sci Transl Med] 2021 Jul 21; Vol. 13 (603).

Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.

Autor: Fontein DB; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., Houtsma D, Nortier JW, Baak-Pablo RF, Kranenbarg EM, van der Straaten TR, Putter H, Seynaeve C, Gelderblom H, van de Velde CJ, Guchelaar HJ

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2014 Apr; Vol. 144 (3), pp. 599-606. Date of Electronic Publication: 2014 Mar 04.

Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.

Autor: Perwitasari DA; Department of Pharmacy, Ahmad Dahlan University, Yogyakarta, Indonesia., Wessels JA, van der Straaten RJ, Baak-Pablo RF, Mustofa M, Hakimi M, Nortier JW, Gelderblom H, Guchelaar HJ

Publikováno v: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2011 Oct; Vol. 41 (10), pp. 1168-76. Date of Electronic Publication: 2011 Aug 11.